AGLE Aeglea BioTherapeutics Inc.

7.37
+0.03  (+0%)
Previous Close 7.34
Open 7.32
Price To Book 3.15
Market Cap 212402663
Shares 28,819,900
Volume 189,850
Short Ratio
Av. Daily Volume 236,274

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 initiation announced July 2016. Enrollment to be completed in 2017.
AEB1102
Acute myeloid leukemia (AML) or Myelodysplastic syndromes (MDS)
Phase 3 trial to be initiated 2Q 2019 with data due 1Q 2021.
Pegzilarginase (AEB1102) - PEACE
Arginase I deficiency
Phase 1 dose escalation data presented at AACR April 15, 2018.
AEB1102
Solid tumors
Phase 1 data presented at ESMO October 2018 noted 1/28 PRs and 8/23 SD.
Pegzilarginase (AEB1102)
Solid tumors
Phase 2 top-line open label data due 1H 2020.
Pegzilarginase (AEB1102) + KEYTRUDA
Small cell lung cancer (SCLC)

Latest News

  1. Aeglea (AGLE) Reports New Positive Data for Pegzilarginase
  2. Aeglea BioTherapeutics Announces New Positive Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 Annual Meeting of the Society for Inherited Metabolic Disorders
  3. Aeglea BioTherapeutics to Present Updated Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency in an Oral Presentation at the 2019 Annual Meeting of the Society for Inherited Metabolic Disorders
  4. Aeglea BioTherapeutics to Participate in Upcoming Investor Conferences
  5. Edited Transcript of AGLE earnings conference call or presentation 7-Mar-19 9:30pm GMT
  6. Aeglea BioTherapeutics (AGLE) Q4 2018 Earnings Conference Call Transcript
  7. Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights
  8. The Aeglea BioTherapeutics Share Price Is Up 11% And Shareholders Are Holding On
  9. Aeglea BioTherapeutics to Host Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights Conference Call
  10. Aeglea aims to raise $60M for treating rare diseases
  11. Aeglea BioTherapeutics Announces Pricing of $60.0 Million Public Offering
  12. Aeglea BioTherapeutics Announces Proposed Public Offering of Common Stock
  13. How Much Of Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Do Institutions Own?
  14. Austin's top-performing stocks of 2018
  15. Is Aeglea BioTherapeutics, Inc. (AGLE) A Good Stock To Buy?
  16. What Investors Should Know About Aeglea BioTherapeutics, Inc.’s (NASDAQ:AGLE) Financial Strength
  17. Aeglea BioTherapeutics Announces Design of Pivotal Phase 3 PEACE Trial Evaluating Pegzilarginase in Arginase 1 Deficiency
  18. Aeglea BioTherapeutics to Present at BMO Capital Markets 2018 Prescription for Success Healthcare Conference
  19. Aeglea BioTherapeutics to Present at Evercore ISI HealthconX Conference
  20. Report: Exploring Fundamental Drivers Behind Aeglea BioTherapeutics, Barnes & Noble Education, GSI Technology, Morgan Stanley, FTS International, and Crown Crafts — New Horizons, Emerging Trends, and Upcoming Developments